News
APUS
--
0.00%
0.00
Based on the provided financial report articles, the title of the article is: "APIMEDS PHARMACEUTICALS US, INC. FORM 10-K FOR THE FISCAL YEAR ENDED DECEMBER 31, 2024
Press release · 4d ago
Preview: Apimeds Pharmaceuticals Us, Inc Set To IPO Tomorrow
Benzinga · 03/04 15:01
IPO Roundup: Kestra Medical Technologies, MNTN and more
Seeking Alpha · 03/03 13:45
U.S. IPO Weekly Recap: Small Asia-Based Names List, As TV Adtech MNTN And Others Join The Pipeline
Seeking Alpha · 03/01 07:45
IPO Roundup: Advanced Biomed, Brag House Holdings and more
Seeking Alpha · 02/25 14:07
Apimeds Pharmaceuticals Us, Inc To Start Trading Tomorrow
Benzinga · 02/20 15:00
IPO Roundup: Anbio Biotechnology, Wellgistics Health and more
Seeking Alpha · 02/18 14:02
U.S. IPO Weekly Recap: Big Listings Post Mixed Results In Busy 7 IPO Week
Seeking Alpha · 02/15 04:50
Catalyst Watch: Apple product event, Walmart earnings, Sandisk debut, and Visa's Investor Day
Seeking Alpha · 02/14 20:00
More
Webull provides a variety of real-time APUS stock news. You can receive the latest news about Apimeds Pharmaceutical U.S, Inc. through multiple platforms. This information may help you make smarter investment decisions.
About APUS
Apimeds Pharmaceuticals US, Inc., is a clinical-stage biopharmaceutical company. The Company is engaged in developing Apitox, an intradermally administered bee venom-based toxin. It is focused on developing Apitox as a potential osteoarthritis (OA) treatment for patients with knee pain who failed to respond adequately to conservative non- pharmacologic therapy and simple analgesics.